By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo ...
Zepbound is a dual-activating medication that combines glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ...
The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...
The U.S. Food and Drug Administration has approved AstraZeneca and partner Daiichi Sankyo's precision drug to treat a type of ...
People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.
Global health highlights include a court pausing a generic version of a heart drug, Novo Nordisk's weight loss trial success, ...
Zyn gains cult status among Gen Z, praised for boosting workouts, alertness, and dubbed O-Zyn-pic for weight loss.
A new analysis finds nearly half of the compounded GLP-1 websites didn’t include information on adverse effects, warnings, ...